

PATENT Customer No. 23,630 Attorney Docket No. 068911-0060

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Matthew L. Tripp et al.

Serial No.:

10/689,856

Filed:

October 20, 2003

Title:

Compositions That Treat Or Inhibit Pathological Conditions Associated With

Inflammatory Response

Examiner:

Michael V. Meller

Docket:

068911-0060

Confirmation No:

3345

Art Unit:

1655

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the U.S. Postal Service via express mail, Express Mail Label No. EV642601807US in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, or facsimile transmitted (571-273-8300) to the US PTO, on the date indicated below.

Date: April 17, 2007

lacqueline Andreu

M.S. Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Enclosed for filing in connection with the above-referenced patent application are the following documents:

- Information Disclosure Statement (2 pages); 1)
- Information Disclosure Statement (Form 1449) (5 pages); 2)
- 3) References cited in IDS (Form 1449) B1-B14 and C1-C57; and
- 4) Return Receipt Postcard.

The commissioner is hereby authorized to charge \$180.00 and any additional fees that may be required, or credit any overpayment, to our Deposit Account No. 50-1133.

Respectfully submitted,

Date: April 17, 2007

Atabak R. Royaee, Reg. No.: 59,037

McDermott Will & Emery LLP

28 State Street

Boston, MA 02109-1775 Telephone: (617) 535-4108 Facsimile: (617) 535-3800



PATENT Customer No. 23,630 Attorney Docket No. 068911-0060

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Matthew L. Tripp et al.

Serial No.:

10/689,856

Filed:

October 20, 2003

Title:

Compositions That Treat Or Inhibit Pathological Conditions Associated

With Inflammatory Response

Examiner:

Michael V. Meller

Docket:

068911-0060

Confirmation No: Art Unit:

3345 1655

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the U.S. Postal Service via Express Mail Label No. EV642601807US, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, or facsimile transmitted (571-273-8300) to the USPTO, on the date indicated below.

Date:

April 17, 2007

cycline Andreu

M.S. Amendment Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

Applicants and their attorney are aware of the following publications and information, listed on the attached Form PTO-1449 Form, and in accordance with 37 C.F.R. §§ 1.56 and 1.97(b) hereby submit these publications for the Examiner's consideration. According to the United States Patent and Trademark Office OG Notices: 05 August 2003, copies of cited U.S. patents and U.S. patent application publications are waived and not submitted with this Statement. Enclosed are copies of foreign references B1-B14, and other references cited as C1-C57. This Statement is being filed before the receipt of a Final Office Action in the above-referenced application.

This Statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed per se as a representation that such publication is prior art. Moreover, the Applicant understands that the Examiner will make an independent evaluation of the cited publications.

U.S. Application Serial No. 10/689,856

Matthew L. Tripp, et al.

Filing Date: October 20, 2003

If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited document does not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents. Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The commissioner is hereby authorized to charge \$180.00 and any additional fees that may be required, or credit any overpayment, to our Deposit Account No. 50-1133.

Respectfully submitted,

Dated: April 17, 2007

Atabak R. Royaee, Reg. No. 59,037 McDERMOTT, WILL & EMERY, LLP.

28 State Street

Boston, Massachusetts 02109-1775

Tel. (617) 535-4108 Fax: (617) 535-3800

SHEET 1 OF 5

INFORMATION DISCLOSURE CITATION IN AN **APPLICATION**

ATTY. DOCKET NO. 068911.0060

SERIAL NO 10/689,856

APPLICANT

Matthew L. Tripp et al.

(PTO-1449)

FILING DATE October 20, 2003 GROUP 1655

ILS PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Document Number Number-Kind Code2 (# known)		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Wher Relevant Passages or Relevan Figures Appear	
	Al	US 3,552,975			Worden,et al.	-	
	A2	US	3,720,517	3/13/1973	Bavisotto, et al.	· · · · · · · · · · · · · · · · · · ·	
	A3	US	3,932,603	6/13/1976	Haas		
	A4	US	3,933,919	1/20/1976	Wilkinson		
	A5	US	3,965,188	6/22/1976	Westermann, et al.		
-	A6	US	4,123,561	10/31/1978	Grant	· · · · · · · · · · · · · · · · · · ·	
	A7	US	4,133,903	1/9/1979	Thiele, et al.		
	A8	US	4,148,873	4/10/1979	Owades		
	A9	US	4,154,865	5/15/1979	Grant	· · · · · · · · · · · · · · · · · · ·	
	A10	US	4,170,638	10/9/1979	Owades		
· · · · · · · · · · · · · · · · · · ·	A11	US	4,401,684	8/30/1983	Versluys		
	A12	US	4,473,551	9/25/1984	Schinitsky		
******	A13	US	4,554,170	11/19/1985	Panzer, et al.		
* *	A14	US	4,644,084	2/17/1987	Cowles, et al.		
	A15	US	4,692,280	9/8/1987	Spinelli		
<u></u>	A16	US	4,767,640	8/30/1998	Goldstein, et al.		
	A17	US	4,857,554	8/15/1989	Kallimanis		
	A18	US	5,006,337	4/9/1991	Motitschke, et al.		
	A19	US	5,013,571	5/7/1991	Hay		
	A20	US	5,073,396	12/17/1991	Todd, Jr.	.	
	A21	US	5,082,975	1/21/1992	Todd, Jr., et al.	······································	
	A22	US	5,155,276	10/13/1992	Paul		
	A23	US	5,166,449	11/24/1992	Todd, Jr., et al.		
	A24	US	5,286,506	2/15/1994	Millis, et al.		
	A25	US	5,296,637	02/012000	Ting, et al.		
	A26	US	5,387,425	2/7/1995	Hsu, et al.		
	A27	US	5,604,263	2/18/1987	Tobe, et al.		
	A28	US	5,624,236	11/23/1993	Ogasahara, et al.		
	A29	US	5,641,517	6/24/1997	Eskeland, et al.	79	
	A30	US	5,827,895	10/27/1998	Nutter, et al.		
	A31	US	5,968,539	10/19/1999	Beerse et al.		
	A32	US	6,020,019	5/21/2002	Ting et al.		
	A33	US	6,129,907	2/1/2000	Sreenivasan, et al.		
		EXAM	INER		DATE CONSIDER	ED	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE **SERIAL NO** ATTY. DOCKET NO. 10/689,856 068911.0060 CITATION IN AN APPLICATION **APPLICANT** Matthew L. Tripp et al. **FILING DATE** (PTO-1449) **GROUP** October 20, 2003 1655 **U.S. PATENT DOCUMENTS EXAMINER'S** CITE **Document Number Publication Date** Pages, Columns, Lines, Where Name of Patentee or Applicant INITIALS NO. MM-DD-YYYY Relevant Passages or Relevant Number-Kind Code2 (# known) of Cited Document Figures Appear A34 US 6,200,594 3/13/2001 Ernest et al. A35 US 6,383,527 5/7/2002 Artman, et al. A36 US 6,391,346 5/21/2002 Newmark, et al. A37 US 6,440,465 8/27/2002 Meisner A38 US 6,447,762 9/10/2002 Galcerá A39 US 6,583,322 6/24/2003 Shalai, et al. A40 US 10/5/2004 6,801,860 Dessen et al. A41 US 20020076452 6/20/2002 Babish, et al. A42 US 20020077299 6/20/2002 Babish, et al. A43 US 20020086062 7/4/2002 Kuhrts 20020086070 A44 US 7/4/2002 Kuhrts A45 US 20030077313 4/24/2003 Schwartz, Robert; et al. A46 US 20030096027 5/22/2003 Babish, et al. US 20030113393 A47 6/19/2004 Babish, et al. 20030133958 A48 US 7/17/2003 Kuno, et al. A49 US 4/15/2004 20040072900 Artman et al. A50 US 20040086580 5/6/2004 Tripp, et al. 20040137096 7/15/2004 A51 US Kuhrts A52 US 20040219240 11/4/2004 Babish, et al. **EXAMINER** DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION				ATTY. DOCKET NO. 068911.0060		SERIAL NO 10/689,856		
				APPLICANT Matthew L. Trip	p et a	l.		
		(PTO-1449)		FILING DATE October 20, 200		GROUP 1655		
			FOREIGN PAT	ENT DOCUMENTS				
EXAMINER'S INITIALS	CITE NO.	Foreign Patent Document Country Codes -Number 4 -Kind Codes (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Wher	columns, Lines e Relevant es Appear	Tra	anslation
				-			Yes	No
	Bl	DE 19841615	3/16/2000	Mueller	A	bstract		
	B2	DE 2212148	9/28/1972	GEN FOODS CORP		bstract		
	В3-	JP 07194351	8/1/1995	Nippon Zoki Pharm Co., Ltd.	А	bstract		
	B4	JP 10025247	1/27/1998	ASAHI BREWERIES LTD	A	bstract		
	B5	JP 409067245	3/11/1997	Ashai Breweries, Ltd.	A	bstract		
	B6	JP 4202138	7/22/1992	Asahi Breweries Ltd	A	bstract		U
	B7	JP 6312924	11/8/1994	Asahi Breweries Ltd	A	bstract		
	B8	JP 63211219	9/2/1988	TAIYO KORYO KK	A	bstract		
	B9	JP 8073369	3/19/1996	Kubo M	A	bstract		
	B10	RU 2045955	10/20/1995	Nikitina	А	bstract		
	B11	WO 00/68356	11/16/2000	Yakima Chief, Inc.				
	B12	WO00/74696	12/14/2000	OXFORD NATURAL PRODUCTS PLC				
	B13	WO02/02582	1/10/2002	Deutsches				
	B14	WO99/44623	9/10/1999	NPS PHARMA INC				
EXAMINER'S	1	OTHER ART		, Title, Date, Pertinent Page		nrinto) titlo of t	ho itom	
INITIALS	CITE NO.	(book, magazine, journal, se city and/or country where pu	erial, symposium,	catalog, etc.), date, page(s),	volume-i	ssue number(s), publishe	er,
		See sheet Nos. 4-5			* .		**	
	 							
					·			
	<u> </u>							
EXAMINER					DATE CO	NSIDERED		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

SERIAL NO INFORMATION DISCLOSURE ATTY, DOCKET NO. 10/689.856 068911.0060 CITATION IN AN APPLICATION **APPLICANT** Matthew L. Tripp et al. **FILING DATE GROUP** (PTO-1449) October 20, 2003 1655 OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.) Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item **EXAMINER'S INITIALS** (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, CITE city and/or country where published. NO "Information on arthrotrimtm product", downloaded from Internet 8/30/02. CI C2 "Information on Zyflamend and Zyflamend PM", downloaded from Internet 8/30/02. C3 "Information on Hops and Beer Flavours", downloaded from internet 02/15/2005 C4 Anto, et al. Pharm. Pharmacol. Comm. 4:103-106 (1998) C5 Bermejo, et al. Rev. Esp. Enferm. Dig. 95: 621-624 and 625-628 (2003) C6 Brown, et al. J. Chem. Soc. 545 (1959) Byrne, et al. J. Chem. Soc. (c):2810 (1971) C7 C8 Carroccio, et al. Clin. Chem. 49:861-867 (2003) C9 Carson, j. Am. Chem. Soc. 73:1850-1851 (1951) C10 Chandra, et al. Indian J. Medical Research 60(1):138-142 (1972) C11 Charlier, et al. Eur. J. Med. Chem. 38:645-659 (2003) C12 CHOU et al. Eur. J. Biochem. 115:207-216 (1981) C13 Chou, et al. Adv enzyme regul 22:27-55 (1984) C14 Chou, et al. J. Biol. Chem. 252:6438-6442 (1977) C15 Chou, et al. J. Theor. Biol. 35:285-297 (1972) C16 Chou, et al. Trends Pharm. Sci. 4:450-454 (1983) C17 Chou, j. Theor. Biol. 59:253-276 (1976) C18 Costa, et al. Digest. Liver Dis. 35:642-647 (2003) C19 Davis, WL. Abstract - Fertiliser, Feeding stuffs and Farm Supplies J. 11:694 (1926) C20 Ding, et al. Biochem. Biophy. Res. Comm. 261:218-223 (1999) C21 Friedman, et al. J Cutan Med. Surg. 6(5):449-459 (2002) C22 Germany, "The Absolutely German Drink," contents of beer, 2004, 5 pages. Goldstein, et al. Am. J. Gastroenterol. 96:1019-1027 (2001) C23 C24 Halter, et al. Gut 49:443-453 (2001) Hamberg, et al. J. Bio. Chem. 246:6713-6721 (1971) C25 C26 Huang, et al. Cancer Res. 51:813-819 (1991) C27 International Search Report for PCT/US02/19617 C28 International Search Report for PCT/US04/16043 Jach, Przegl Dermatol. 65(4):379-382 (1978) C29 C30 Kanematsu, et al. J Bone Miner Res 12(11):1789-1796 (1997) Lopes, Curr. Med Res Opin. 8:145-149 (1982) C31 Meling, et al. Scand. J. Gastroenterol. 31:339-344 (1996) C32 **EXAMINER DATE CONSIDERED**

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

				SHEET <u>5</u> OF <u>5</u>					
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)			ATTY. DOCKET NO. 068911.0060	SERIAL NO 10/689,856					
			APPLICANT Matthew L. Tripp et al.						
			FILING DATE October 20, 2003	GROUP 1655					
		OTHER ART (Including Author,	Title, Date, Pertinent Page	s, Etc.)					
EXAMINER'S INITIALS	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.							
	C33	Noreen, et al. J. Nat. Prod 61:2-7 (1998)							
	C34	Pairet, et al. Inflamm. Res 47, Supplement 2s93-s101 (1998)							
	C35	Panglisch, monafsschrift fuer brauwissen scha							
	C36	Pippa, et al. Scand. J. Gastroenterol. Suppl. <u>167</u> :32-35 (1989)							
	C37	Plewig, et al. J Invest. Dermatol. 65(6):532-536 (1975)							
	C38								
	C39	Ringbom, et al. J. Nat Prod <u>61</u> :1212-1215 (1998)							
	C40	Røseth, digest. Liver Dis. <u>35</u> :607-609 (2003)							
	C41	Schjerven, et al. Br. J. Dermatol. <u>149</u> :484-491 (2003)							
	C42	Shah, et al. Gut 48:339-346 (2001)							
	C43	Shimamura, et al. Biochem. Biophys. Res. Comm. 289:220-224 (2001)							
	C44	Shureiqi, et al. Cancer res. 61:6307-6312 (2001)							
	C45	, , , , , , , , , , , , , , , , , , , ,							
	C46								
	C47	Sain, 67 an Canton 100, 20, 17, 120 (1700)							
	C48	Tagashira, et al., Biosci. Biotech. Biochem. 5							
	C49	Thomas m. Newmark and paul schulick, 'Bey		thritis, cancer & alzheimer's					
	C50	disease," hohm press (2000) release 7; pp. 147-151, 248. Tibble, et al. Drugs Today 37:85-96 (2001)							
	C51	Tibble, et al. Gut 45:362-366 (1999)							
	C52	Tobe, et al. Biosci. Biotech. Biochem 61(1):1	58-159 (1997)						
	C53	Wang, et al. Free Radical Biology & Medicine 27:612-616 (1999)							
	C54	Warner, et al. Proc Natl Acad Sci USA <u>96</u> :7563-7568 (1999)							
	C55	Yamamoto, et al. Abstract - Prostaglandins & Other Lipid Mediators 59:1-235 (1999)							
	C56	Yamamoto, FEBS Letters 465:103-106 (2000		N					
	C57	Yui, et al. Biol. Pharm. Bull. 26:753-760 (2003)							
			·						
			· · · · · · · · · · · · · · · · · · ·						
		EXAMINER	DATE	CONSIDERED					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.